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Abstract
Background
Mycobacterium tuberculosis infection is a leading cause of infectious death worldwide.
Gene-expression microarray studies profiling the blood transcriptional response of tubercu-
losis (TB) patients have been undertaken in order to better understand the host immune
response as well as to identify potential biomarkers of disease. To date most of these stud-
ies have focused on pulmonary TB patients with gene-expression profiles of extra-pulmo-
nary TB patients yet to be compared to those of patients with pulmonary TB or sarcoidosis.
Methods
A novel cohort of patients with extra-pulmonary TB and sarcoidosis was recruited and the
transcriptional response of these patients compared to those with pulmonary TB using a
variety of transcriptomic approaches including testing a previously defined 380 gene meta-
signature of active TB.
Results
The 380 meta-signature broadly differentiated active TB from healthy controls in this new
dataset consisting of pulmonary and extra-pulmonary TB. The top 15 genes from this meta-
signature had a lower sensitivity for differentiating extra-pulmonary TB from healthy con-
trols as compared to pulmonary TB. We found the blood transcriptional responses in
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pulmonary and extra-pulmonary TB to be heterogeneous and to reflect the extent of symp-
toms of disease.
Conclusions
The transcriptional signature in extra-pulmonary TB demonstrated heterogeneity of gene
expression reflective of symptom status, while the signature of pulmonary TB was distinct,
based on a higher proportion of symptomatic individuals. These findings are of importance
for the rational design and implementation of mRNA based TB diagnostics.
Introduction
Mycobacterium tuberculosis (Mtb) continues to be a significant cause of mortality and morbid-
ity worldwide [1]. In 2013 there were 9 million cases of active tuberculosis (TB) resulting in 1.5
million deaths worldwide, of these active TB cases approximately 15% were notified as extra-
pulmonary TB [1]. Common sites of extra-pulmonaryTB infection include the pleura, lymph
nodes, meninges, bone and genito-urinary tract [2]. Extra-pulmonaryTB can be challenging to
diagnose compared to pulmonary TB as it is often not considered during clinical evaluation
and diagnostic samples can bemore difficult to obtain [3, 4].
Whole genome expression analysis of human whole blood as well as peripheral blood
mononuclear cells (PBMC) has been widely used to profile the host transcriptional response in
active TB and identify potential biomarkers for use in diagnostics (reviewed in [5]). An inter-
feron-dominated 393 transcript signature was identified from human whole bloodwhich was
present in active TB and absent in the majority of healthy and latently infected individuals and
was shown to correlate with the extent of radiographic lung disease [6]. This finding of enrich-
ment for interferon signalling has since been reported in multiple subsequent studies [7–11].
Other studies have, in addition to interferon signalling, identified immunological pathways
that may be relevant to the pathogenesis of active TB such as TLR signalling, complement as
well as enrichment for T- and B-cell function gene expression [6–9, 11–15]. Two large studies
have included extra-pulmonaryTB patients within their active TB cohort, but no sub-group
analysis was undertaken to determine if there was a transcriptional signature unique to extra-
pulmonary TB [16, 17]. Therefore the question of whether there is a difference in the blood
transcriptional signature between pulmonary and extra-pulmonaryTB has not been answered.
We recently published a 380 gene meta-signature (S1 Table) of active TB compared to
healthy controls [18], which represents an attempt to identify the most consistently differen-
tially expressed genes across the published publicly available datasets [18]. Similar to the indi-
vidual published studies the 380 gene meta-signature was found to be enriched for immune
response pathways including multiple pattern recognition receptors, cytokines, the inflamma-
some, complement and immunoglobulin pathways [18].
We herein used this published derived gene set as well as other transcriptional analysis tools
to test similarities and differences between pulmonary TB and extra-pulmonaryTB in a novel
dataset and now report heterogeneity drivenmainly by the extent of symptoms.
Materials and Methods
Ethics
This study was approved by the Central London 3 Research Ethics Committee (09/H0716/41).
All participants gave written informed consent.
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Clinical cohort
Recruitment took place between 2011 and 2014. Sites for recruitment were the Royal Free and
Guy’s & St Thomas’ Hospitals, London, United Kingdom. Healthy controls and the majority of
pulmonary TB patients were chosen from an existing bank of globin reduced RNA samples.
These subjects had consented to their samples being used in further approved studies. Patients
identified from this bank were selected on cohort group, age, sex and ethnicity. Diagnosis of
active TB was based on the following: positive mycobacterial culture result from the site of dis-
ease; or caseating granuloma on biopsy and/or clinical/radiological features consistent with
active TB and a good response to therapy. Sarcoidosis patients all had mediastinal disease with
compatible histology and clinical/radiological features to support a diagnosis of sarcoidosis
and negative mycobacterial cultures. Patients were excluded if they were immunosuppressed
either through disease (such as HIV, diabetes or autoimmune diseases),medication or had sig-
nificant co-morbidities affecting the pulmonary system.
Microarray
Human whole blood RNA was isolated, globin reduced and amplified as described previously
[6, 19]. 750 ng of cRNA was hybridized to Illumina Human HT-12 V4 BeadChip arrays and
scanned on Illumina iScan. GenomeStudio was used to perform quality control and generate
signal intensity. Microarray analysis was undertaken using GeneSpring GX 13.0. Per sample
normalisation (75th centile) and per transcript normalisation (median of all samples) was
performed.Microarray data were deposited in the NCBI Gene Expression Omnibus (GEO)
with series accession number (GSE83456). All data collected and analysed in these experi-
ments adhere to the Minimal Information About a Microarray Experiment (MIAME)
guidelines.
Expression analysis
Molecular Distance to Health (MDTH), was calculated using methodologypreviously
described [20], for defined groups of genes (group of genes defined in legend of Figures) rela-
tive to a control group (detailed in legend of Figure). Additionally, the MDTH was calculated
using the same methodologybut now using 3409 transcripts, which represent the transcripts
from 38 annotated modules [21]. Z-scores were derived from the respectiveMDTH’s and cal-
culated relative to the control group.
Modular analysis was undertaken using log2 transformed normalised data [21].
Differentially expressed genes identified from new dataset for TB and sarcoidosis involved
groups being compared to the healthy control cohort (transcripts filtered which were not sig-
nificantly detected from background in at least 10% of samples, low expressed transcripts fil-
tered (less than 2 fold change frommedian in 10% of samples), followed by statistical testing
(independent t-test with Benjamini Hochberg multiple testing correction (q-value<0.05)
between groups of interest). Transcripts were than matched to Entrez Gene identifiers; dupli-
cates (retaining those with the largest fold change difference) and non-matched transcripts
were filtered.
Statistical analyses
GraphPad Prism 6 or Microsoft Excel (2010) were used for statistical analysis, details of statisti-
cal testing given in figure legends.
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Results
Testing the meta-signature in a new dataset reveals differences in the
transcriptional response of pulmonary and extra-pulmonary patients
A new cohort of extra-pulmonary and sarcoidosis patients was recruited together with an exist-
ing bank of pulmonary TB and healthy controls formed the dataset for analysis (Cohort details;
S2 and S3 Tables). There was no difference in gender frequency (Fig 1A) between groups how-
ever there were differences in the group composition with regard to ethnicity and age, with the
sarcoidosis group being significantly older than the other groups and tending to have less
patients of Indian subcontinent background (Fig 1B and 1C). Total white cell count was
Fig 1. Clinical parameters of patients included in microarray dataset. (A) percentage of cohort by sex (B) percentage of cohort by ethnicity (ISC;
Indian sub-continent) and (C) age (mean; min-max bars). Whole blood composition; (D) total leukocytes (E) Granulocytes (F) lymphocytes and (G)
monocytes. Statistical tests: Kruskal Wallis with Dunn’s multiple testing correction.
doi:10.1371/journal.pone.0162220.g001
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significantly elevated in Pulmonary TB patients compared to the other groups (Fig 1D), this
was mainly due to increased numbers of granulocytes compared to the other groups (Fig 1E).
Total lymphocyte count was significantly higher in healthy controls compared to all the groups
(Fig 1F) and monocytes were significantly elevated in Pulmonary and Extra-pulmonaryTB
patients compared to Healthy controls (Fig 1G).
The previously defined 380 meta-signature genes [18] (S1 Table, mapped to 687 Illumina
transcripts, of which 113 transcripts were excluded as they were not significantly detected from
background in 10% of samples) were used for analysis in this new dataset. Hierarchical cluster-
ing of the dataset (healthy controls, pulmonary and extra-pulmonaryTB patients only)
revealed that the 380 meta-signature genes (S1 Table) were able to separate healthy controls
from the majority of both pulmonary and extra-pulmonaryTB patients, although a small num-
ber of TB patients clustered together with the healthy controls (Fig 2A). Using the most consis-
tently identified genes from the meta-analysis as potential biomarkers (15 genes which were
identified in 15 or more meta-analysis data-sets, S1 Table) and calculating a molecular score
for these genes, there was a greater sensitivity in identifying pulmonary TB patients than extra-
pulmonary TB patients from healthy controls (Fig 2B).
Transcriptional signatures in TB reflect symptom status of individuals
There was a significant difference in the molecular distance to health (MDTH) of both pulmo-
nary TB and extra-pulmonaryTB patients as compared to healthy controls (Fig 3A).
Fig 2. Testing the meta-signature and the most consistently identified genes in a new dataset. (A) The 380 gene meta-
signature were mapped to 687 Illumina transcripts, of which 113 transcripts were excluded as they were not significantly detected from
background in 10% of samples. Hierarchical clustering (Pearson uncentred (cosine) with averaged linkage) on individuals and
transcripts broadly cluster healthy controls from pulmonary and extra-pulmonary TB patients. (B) Receiver operator curves for extra-
pulmonary and pulmonary cohorts against healthy controls using MDTH derived from the most consistently identified genes (15 genes
identified in at least 15 of the meta-analysis datasets [18]–representing the most robustly identified genes in that analysis, healthy
controls used as control group for MDTH) as potential diagnostic biomarker. Both prediction results were validated using k-fold cross
validation with k equal to 10 with 1,000 iterations. The mean AUC for the EPTB and PTB validation results are 0.865 (95% confidence
interval: 0.857–0.872) and 0.977 (95% confidence interval: 0.974–0.981) respectively.
doi:10.1371/journal.pone.0162220.g002
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Pulmonary TB had a significantly higherMDTH compared to extra-pulmonaryTB (Fig 3A).
The MTDH was not influenced by the ethnicity of the TB patients (S1A Fig) or byM. tubercu-
losis culture status in extra-pulmonaryTB patients (S1B Fig).
Presence of one of the following symptoms: night sweats, fever, weight loss, chest pain or
cough resulted in a significantly higherMDTH compared to healthy controls; there was no
additive effect of increasing number of symptoms in terms of magnitude of MDTH (Fig 3B).
Absence of any of the above symptoms resulted in no significant difference in MDTH score
from healthy controls. There were differences in symptom prevalence depending on the site of
disease (Fig 3C). The meanMDTH of the patients grouped by site of disease significantly cor-
related with the percentage of patients within the group having one or more symptom (Fig
3D). There was no difference in MDTH score of extra-pulmonary patients dependent on cul-
ture status (S1C Fig).
Upon individual modular analysis, there was no apparent site-specificmodular patter.
Instead, presence of any of the five symptoms seemed to influence the modular pattern
observed (Fig 4A). Molecular scoring of the genes withinmodules annotated as “inflammation”
revealed no significant difference between healthy controls and the asymptomatic group of TB
patients, in contrast to the significant difference between asymptomatic and symptomatic pop-
ulations (Fig 4A and 4B). For the interferon modules there was a significantly higher score for
the symptomatic group compared to the asymptomatic group (Fig 4A and 4B). While there
were significantly higher lymphocyte and significantly lower granulocyte and monocyte counts
in the asymptomatic group compared to the symptomatic TB patients, there was considerable
overlap between the two populations (Fig 4C).
Fig 3. Molecular distance to health is linked to symptoms status and site of disease. (A) Molecular distance to health (MDTH) calculated for each
individual (from 3409 transcripts which represent the transcripts of the 38 annotated modules shown in Fig 2A, healthy controls used as the control
group). Individuals grouped by disease status, (median value, error bars SD) statistical testing Kruskal Wallis with Dunn’s multiple testing correction.
(B) Patients grouped by number of reported symptoms; night sweats, fever, weight loss, chest pain or cough (median value, error bars SD) statistical
testing Kruskal Wallis with Dunn’s multiple testing correction. (C) Patients grouped by site of disease and number of reported symptoms (as previous).
(D) Mean MDTH (error bars, Standard error of the mean) plotted for each site of disease against % of the cohort suffering from one or more symptom
(from list of symptoms described previously). Blue line represents Pearson’s correlation (R2 0.95, p = 0.0090).
doi:10.1371/journal.pone.0162220.g003
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Fig 4. Symptom status linked to alteration in modular profile and blood counts. (A) Individual modular analysis for all TB patients
grouped by symptom status and site of disease, boxed are modules annotated as interferon or inflammation. 38 annotated modules are
displayed as a heatmap with red indicates significant over-abundance of transcripts and a blue indicating significant under-abundance
(p <0.05). The colour intensity represents the percentage of genes in that module that are significantly differentially expressed. (B) MDTH
calculated for all interferon module transcripts and all inflammatory module transcripts (healthy controls used as control group). TB patients
grouped according to symptom status (median value, error bars SD) statistical testing Kruskal Wallis with Dunn’s multiple testing correction.
(C) TB patients grouped according to symptom status with lymphocyte, granulocyte and monocytes counts shown (median value, error bars
SD) statistical testing Mann-Whitney U.
doi:10.1371/journal.pone.0162220.g004
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Overlap in expression profiles between sarcoidosis and extra-
pulmonary TB patients
Analysis of all the TB patients from this new dataset identified 927 genes (S4 Table) as being
differentially regulated compared to healthy controls and 883 genes (S4 Table) differentially
regulated between sarcoidosis patients and healthy controls (Fig 5A). Overlapping these two
gene lists revealed that 709 genes were commonly expressed between the two conditions com-
pared to healthy controls, of which 15 had been previously identified from the meta-analysis as
those most consistently expressed in TB (Fig 5A, S4 Table). Nine of the top 10 upregulated
genes by fold change of TB compared with healthy controls were also found within the top 10
upregulated genes by fold change of sarcoidosis compared with healthy controls (Table 1).
Of those genes which were identified in only TB or sarcoidosis compared with healthy con-
trols, only one (RNF182) was two-fold different betweenTB and sarcoidosis (S4 Table). Using
the Bloom et al 144 transcript list [19] by hierarchical clustering it was possible again to sepa-
rate the majority of sarcoidosis patients from those with pulmonary TB (Fig 5B), but not from
mediastinal TB (Fig 5C).
Calculating the molecular scores for the 380 meta-signature for all patients and ranking
them in order of z score (compared to healthy controls) revealed that there was an overlap
between the three groups, with pulmonary TB patients tending towards the higher end and
extra-pulmonary and sarcoidosis patients the lower end of the spectrum(Fig 5D). Indeed, for
all three outcomes the mean of pulmonary TB patients was significantly higher than both the
extra-pulmonaryTB and sarcoidosis patients. However, any individual regardless of disease
type could lie anywhere within this range. This observationwas consistent for MDTH and
molecular scores for the interferon modules. Patients with none of the 5 listed symptoms,
regardless of their disease, tended to have the lowest z scores (Fig 5D).
Discussion
This study is the first to our knowledge to attempt to identify blood transcriptional signatures
associated with the site ofMtb infection.We show that the transcriptional response is similar
across sites of disease as measured from the blood although the magnitude of response varies
and this is mainly associated with the presence or absence of symptoms and probably the site
of the infection.
There were differences in the demographic composition of the cohorts in this study.
Patients diagnosedwith sarcoidosis were older and more likely to be of white or black ethnic
background. This skewing in terms of age and ethnicity is well described in sarcoidosis [22,
23]. TB in the UK tends to be diagnosed from the immigrant population, in particular those
from the Indian subcontinent [24], with extra-pulmonaryTB beingmore common in those of
Asian and African origin [25–27]. Hence the differences in ethnic composition between our
clinical groups are likely to be due to a combination of these factors. These differences in group
composition did not affect the transcriptional responses observed in our study. Similarly,
whole blood cell composition in this study at the group level was found to be altered in pulmo-
nary and extra-pulmonaryTB compared to healthy controls with increasedmonocytes and
granulocytes and decreased lymphocytes as has been previously described [28].
Extra-pulmonaryTB representsMtb infectionwhich has spread haematogenously or via
the lymphatic system from the lung. It is hypothesised that this spread happens during initial
infection and that extra-pulmonary diseasemay represent reactivation rather than primary dis-
ease [4]. It has long been recognised that there is variation in symptoms and bacterial load
dependent on site of disease, hence differences in the transcriptional signature may reflect vari-
ation in bacterial burden at the site of disease [4, 29–31], or in the site specific host immune
Blood Transcriptome of Extra-Pulmonary and Pulmonary Tuberculosis
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Fig 5. Tuberculosis and sarcoidosis have similar differentially regulated genes. (A) Differentially
expressed genes identified from new dataset for TB and sarcoidosis groups compared to healthy controls
(transcripts filtered which were not significantly detected from background in at least 10% of samples, low
expressed transcripts filtered (less than 2 fold change from median in 10% of samples), followed by statistical
testing (independent t-test with Benjamini Hochberg multiple testing correction (q-value <0.05) between groups of
interest). Transcripts were matched to Entrez gene identifiers and duplicates and non-matched transcripts
filtered. Venn diagram showing the overlap of DEGs between these two diseases and the most significant 15
gene list from the meta-analysis. (B) Heatmap of normalised expression using the Bloom et al 144 transcript list
are able to broadly differentiate pulmonary TB patients from sarcoidosis patients. Clustering (Pearson’s
uncentred (Cosine) with averaged linkage) on transcripts (rows) and individual patient blood samples (columns).
(C) The same 144 transcript list (16) is unable to differentiate between mediastinal TB patients and sarcoidosis
patients by clustering (as before) (D) Molecular scores calculated for transcripts from 380 gene meta-signature,
MDTH and transcripts representing the interferon modules (healthy controls acting as control group). Z scores
calculated (with healthy controls used as reference group for calculating mean and SD) and then TB patients and
sarcoidosis patients ranked according to Z score of the 380 gene meta-signature. For all three outcomes the
Blood Transcriptome of Extra-Pulmonary and Pulmonary Tuberculosis
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response which may be reflected in the blood. Gene expression signatures of TB patients have
previously been linked with bacterial burden, with a prior study showing reduced sensitivity of
a whole genome expression derived disease risk score with decreased culture positivity in chil-
dren [17]. Equally, with respect to complement which has been identified as one of the key
findings in severalmicroarray studies,C1q expression levels correlated with sputum smear pos-
itivity and diminishedwith treatment [12, 32]. Our findings of differences in MDTH (and
symptoms) based on the site of diseasemay therefore be linked to differences in bacterial bur-
den or the host site specific immune response. Integration of both host transcriptional response
and more accurate quantitation of total mycobacterial burden may result in a better under-
standing of what drives the blood host transcriptional response.
Whilst it was possible to again here to distinguish pulmonary TB from sarcoidosis using our
previously described gene set [19], it was not possible to distinguish sarcoidosis and mediasti-
nal TB by hierarchical clustering. The inability to distinguish sarcoidosis and mediastinal TB,
is possibly due to the lower symptom status of mediastinal extra-pulmonaryTB cohorts versus
pulmonary TB cohorts. This would fit with our findings that the magnitude of the transcrip-
tional response as measured from the blood is mainly associated with the presence or absence
of symptoms. Previous studies which had identified differentially expressed genes between sar-
coidosis and TB had used only pulmonary TB patients as their comparator group [9, 19, 33].
We show that compared to healthy controls the gene expression signature of TB (including
pulmonary and extra-pulmonary patients) is very similar to sarcoidosis.We show that individ-
uals from each disease state (Pulmonary TB, Extra-pulmonaryTB or sarcoidosis) can lie any-
where along this spectrumof gene expression including some clustering together with healthy
controls. However when taken at the group level differences in magnitude of expression can be
observedbetween pulmonary TB and the other disease states.
Both TB and sarcoidosis are granulomatous diseases, and together with another granuloma-
tous diseasemelioidosis they have been shown to have similar gene expression signatures to
TB [9, 19, 33, 34]. Despite these similarities, it may still be possible using clinical parameters
mean of pulmonary TB patients was significantly higher than both the extra-pulmonary TB and sarcoidosis
patients (p<0.05). Differences among means were tested with a generalized linear model assuming a normal
distribution and a Bonferroni multiple testing correction. No symptoms indicates absence of any of the five
symptoms listed previously.
doi:10.1371/journal.pone.0162220.g005
Table 1. Top 10 differentially upregulated genes in TB and sarcoidosisa.
Tuberculosis Sarcoidosis
Gene Log2 FC Gene Log2 FC
SERPING1 3.83 ANKRD22 3.35
ANKRD22 3.82 SERPING1 3.20
BATF2 3.61 BATF2 3.02
FCGR1C 3.04 IFIT3 2.67
LOC728744 3.04 FCGR1A 2.54
GBP6 3.03 FCGR1C 2.52
C1QB 3.02 GBP6 2.52
FCGR1A 3.02 FCGR1B 2.50
FCGR1B 2.90 RAP1GAP 2.44
IFIT3 2.84 LOC728744 2.42
a Significantly upregulated genes as measured by fold change compared to healthy controls.
doi:10.1371/journal.pone.0162220.t001
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and risk stratification to utilisemRNA expression based diagnostics to differentiate between
diseases as has been done for active and latent TB [6–9, 15–18, 35].
We show here for the first time that blood based transcriptional signatures in pulmonary
and extra-pulmonaryTB differ as a result of the symptom status and site of the disease in each
individual. These findings have implications for design and implementation of mRNA expres-
sion tools to support diagnostics and treatment monitoring of TB.
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